Cibus, Inc. (CBUS) vs Retension Pharmaceuticals, Inc. (RTSN)

Cibus, Inc. CBUS 1.16 −6.45%
Retension Pharmaceuticals, Inc. RTSN 10.58 −8.79%

Cibus, Inc. and Retension Pharmaceuticals, Inc. are both Biotechnology companies. Cibus, Inc. and Retension Pharmaceuticals, Inc. are of similar size ($96.6M and $94.8M).

Metric	CBUS	RTSN	Biotechnology median
P/E	n/m	—	10.26
P/S	20.48	—	9.18
P/B	6.02	—	2.05
Price to free cash flow	n/m	—	24.81
EV/EBITDA	n/m	—	0.65
EV/Sales	16.03	—	8.98
Earnings yield	(142.24%)	—	(34.89%)
Free cash flow yield	(51.98%)	—	(24.52%)

Metric	CBUS	RTSN	Biotechnology median
Gross margin	100.00%	—	65.16%
Operating margin	(1,450.59%)	—	0.00%
Net margin	(2,258.89%)	—	0.00%
Free cash flow margin	(1,064.60%)	—	0.00%
Return on equity	(219.97%)	—	(50.12%)
Return on assets	(29.77%)	—	(45.60%)
Return on invested capital	0.00%	—	0.00%

Metric	CBUS	RTSN	Biotechnology median
Revenue growth (TTM)	(10.30%)	—	6.26%
EPS growth (last fiscal year)	74.33%	—	29.88%
Revenue growth, 5-year CAGR	(31.34%)	—	9.75%
Net income growth, 5-year CAGR	0.00%	—	0.00%

Metric	CBUS	RTSN	Biotechnology median
Debt to equity	0.00	—	0.00
Current ratio	1.62	—	4.89
Net debt to EBITDA	(0.28)	—	1.01

Metric	CBUS	RTSN	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	CBUS	RTSN	Biotechnology median
Market cap	94.77m	96.61m	172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack